Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 3193 (MIR3193) is a human microRNA gene that encodes a non-coding RNA molecule, part of the microRNA family which are 20–24 nucleotide RNAs that regulate gene expression post-transcriptionally by binding to target mRNAs, leading to their translational inhibition or destabilization. MIR3193 is processed from a primary transcript by Drosha and Dicer enzymes, resulting in a mature microRNA incorporated into the RISC complex to mediate its effects. There is limited functional or disease-specific data for MIR3193: while its dysregulation has been reported in some databases, its biological and pathological roles remain largely uncharacterized and it is not currently established as a therapeutic target or biomarker. MicroRNAs are a large family of non-coding RNAs involved in gene regulation, and the MIR3193 gene codes for one such microRNA. The biogenesis and function of microRNAs is well established: they are transcribed, processed by Drosha/Dicer, and incorporated into RISC for gene regulation via mRNA targeting. There is no evidence that MIR3193 is a drug target, receptor, enzyme, transporter, or transcription factor. It is strictly a non-coding gene product. While some databases note statistical associations (e.g., with Leopard syndrome 1), this is not equivalent to the causal or mechanistic roles seen with established drug targets, nor does it place MIR3193 into cancer, cardiovascular, or neurodegenerative disease pathways as of current literature. There are no known drugs, mechanisms of action, or biomarker status for MIR3193, nor are there described safety concerns for targeting it, as it is not targeted therapeutically. This entry differs from well-characterized microRNAs like miR-193a-3p (which has reported tumor suppressor roles and more established disease biology). There is no indication of misspelling or fundamental error for this target, but it is not an established or actionable therapeutic target according to the current major databases or literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 3193 (MIR3193).